5-hydroxy-2-methyl-1-(phenylmethyl)-1H-indole-3-acetic acid methyl ester | 163735-05-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 5-hydroxy-2-methyl-1-(phenylmethyl)-1H-indole-3-acetic acid methyl ester
• 英文别名: methyl (1-benzyl-5-hydroxy-2-methyl-1H-indol-3-yl)acetate；methyl 2-(1-benzyl-5-hydroxy-2-methylindol-3-yl)acetate
• CAS: 163735-05-5
• 化学式: C₁₉H₁₉NO₃
• 分子量: 309.365
• InChiKey: JTALJLNJPUQIET-UHFFFAOYSA-N

物化性质

• 沸点：
  515.5±50.0 °C(Predicted)
• 密度：
  1.17±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  51.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-hydroxy-2-methyl-1-(phenylmethyl)-1H-indole-3-acetic acid methyl ester 在 sodium hydroxide 、 sodium hydride 作用下， 以 甲醇 为溶剂， 反应 99.5h， 生成 4-(1-Benzyl-3-carboxymethyl-2-methyl-1H-indol-5-yloxy)-butyric acid
  参考文献：
  名称：

  Indole Inhibitors of Human Nonpancreatic Secretory Phospholipase A₂. 2. Indole-3-acetamides with Additional Functionality

  摘要：

  As reported in our previous paper, a series of indole-3-acetamides which possessed potency and selectivity as inhibitors of human nonpancreatic secretory phospholipase A(2)(hnps-PLA(2)) was developed. The design of these compounds was based on information derived from x-ray crystal structures determined for complexes between the enzyme and its inhibitors. We describe here the further implementation of this structure-based design strategy and continued SAR development to produce indole-3-acetamides with additional functionalities which provide increased interaction with important residues within the enzyme active site. These efforts led to inhibitors with substantially enhanced potency and selectivity.

  DOI：

  10.1021/jm960486n
• 作为产物：
  描述：

  2-(1-苄基-5-甲氧基-2-甲基吲哚-3-基)乙酸 在 甲醇 、 甲烷磺酸 、 三溴化硼 作用下， 反应 23.5h， 生成 5-hydroxy-2-methyl-1-(phenylmethyl)-1H-indole-3-acetic acid methyl ester
  参考文献：
  名称：

  Indole Inhibitors of Human Nonpancreatic Secretory Phospholipase A₂. 2. Indole-3-acetamides with Additional Functionality

  摘要：

  As reported in our previous paper, a series of indole-3-acetamides which possessed potency and selectivity as inhibitors of human nonpancreatic secretory phospholipase A(2)(hnps-PLA(2)) was developed. The design of these compounds was based on information derived from x-ray crystal structures determined for complexes between the enzyme and its inhibitors. We describe here the further implementation of this structure-based design strategy and continued SAR development to produce indole-3-acetamides with additional functionalities which provide increased interaction with important residues within the enzyme active site. These efforts led to inhibitors with substantially enhanced potency and selectivity.

  DOI：

  10.1021/jm960486n

文献信息

• 1H-indole-3-acetamide sPLA.sub.2 inhibitors
  申请人：Eli Lilly and Company

  公开号：US05684034A1

  公开（公告）日：1997-11-04

  A class of novel 1-indole-3-acetamides represented by the formula; ##STR1## is disclosed together with the use of such indole compounds for inhibiting sPLA.sub.2 mediated release of fatty acids.

  一类由以下式表示的新型1-吲哚-3-乙酰胺类化合物被揭示，同时还公开了利用这类吲哚化合物抑制sPLA.sub.2介导的脂肪酸释放的用途。
• 1H-indole-3-acetic acid hydrazide sPLA.sub.2 inhibitors
  申请人：Eli Lilly and Company

  公开号：US05578634A1

  公开（公告）日：1996-11-26

  A class of novel 1H-indole-3-acetic acid hydrazides is disclosed together with the use of such indole compounds for inhibiting sPLA.sub.2 mediated release of fatty acids (e.g., arachidonic acid) for treatment of conditions such as septic shock.

  本发明揭示了一类新颖的1H-吲哚-3-乙酸肼衍生物，并利用这种吲哚化合物抑制sPLA.sub.2介导的脂肪酸（例如花生四烯酸）的释放，以治疗诸如脓毒性休克等病症。
• 1H-indole-3-acetamide sPLA2 inhibitors
  申请人：Eli Lilly and Company

  公开号：US06252084B1

  公开（公告）日：2001-06-26

  A class of novel 1H-indole-3-acetamides is disclosed together with the use of such indole compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of conditions such as septic shock.

  一类新型1H-吲哚-3-乙酰胺被揭示，以及使用这些吲哚化合物抑制sPLA2介导的脂肪酸释放，用于治疗诸如感染性休克等疾病的方法。
• 1H-indole-3-acetic acid hydrazide sPLA2 inhibitors
  申请人：ELI LILLY AND COMPANY

  公开号：EP0620214B1

  公开（公告）日：1999-03-03
• 1H-indole-3-acetamide derivatives as sPLA2 inhibitors
  申请人：ELI LILLY AND COMPANY

  公开号：EP0620215B1

  公开（公告）日：1999-08-18